CDMO for microbial cell lines and processes

ARTES Biotechnology – the best partner to get your recombinant product – cell line and process development based on yeast and bacteria

CDMO service

The pharmaceutical industry is faced with a multitude of challenges throughout the lengthy and complex processes involved in the development and manufacturing of new drug substances. A partnership with the appropriate contract development and manufacturing organization (CDMO) facilitates the market introduction of pharmaceutical products by providing expertise and reducing costs.

ARTES’ CDMO services:

• microbial cell line and process development
• manufacturing of high quality test and preclinical material
• vaccine development

License Offer

We offer our customers a variety of pre-developed processes for the production of recombinant proteins.
These “ready-to-use” processes for biosimilars, vaccines, enzymes and other products save the customer development time and costs compared to newly manufactured processes. This allows the targeted product to be launched on the market much faster and more reliable.
Our customers receive proprietary cell lines and all necessary documentation during a technology transfer, together with extensive after-sales support.

Licenses are available at fair prices.

ARTES’ license offer:

• ready-to-use processes  for biosimilars, vaccines and enzymes from ARTES’ internal development reducing time-to-market
• technology transfer and licensing of our proprietary cell lines and processes

Recombinant proteins as reagents

We offer recombinant antigens, enzymes and functional proteins as research reagents.
These reagents are produced with our yeast technology platform Hansenula polymorpha or with the bacterium E. coli.

ARTES’ reagents:

• antigens
• enzymes
• functional proteins